# Debate prop_0635__gpt-5.6-high__gpt-6-astra-high__s0__tpl_placement_active_20260813a

- topic_id: prop_0635
- proposition: AI model providers should face product-liability-style responsibility for foreseeable harms caused by deployed model behavior when reasonable safeguards were not implemented.
- model_pro: gpt-5.6-high
- model_con: gpt-6-astra-high
- side_swap: False

## Turn 1: PRO Opening

- model: gpt-5.6-high
- raw_words: 325
- clipped_words: 325
- claim_ids: [P1.1], [P1.2], [P1.3], [P1.4], [P1.5], [P1.6], [P1.7]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[P1.1] When a company releases a powerful model, it is not merely publishing ideas. It is placing a designed, tested, continuously managed product into real workflows. The provider chooses the training process, deployment channel, access controls, evaluations, warnings, monitoring, and updates. If foreseeable harm follows because reasonable safeguards were omitted, responsibility should follow that control.
[P1.2] The proposition is deliberately bounded. It does not impose liability whenever anyone uses AI badly, nor does it demand perfect safety. A claimant must show actual harm, causal connection to deployed model behavior, reasonable foreseeability, and the absence of proportionate safeguards. Providers could defend themselves by showing robust testing, clear limits, appropriate access restrictions, effective monitoring, or an intervening user’s extraordinary misuse.
[P1.3] Responsibility can also be divided among providers, deployers, and users according to their contribution. That is product-liability-style accountability, not automatic punishment.
[P1.4] This rule aligns incentives where voluntary promises cannot. Providers capture the benefits of rapid deployment, while victims otherwise absorb costs they neither chose nor could assess. A patient cannot inspect whether a medical chatbot was tested for dangerous fabrication. A business targeted by scalable AI-enabled impersonation cannot know whether basic abuse controls were skipped.
[P1.5] The provider has superior information about model failure modes and is usually better positioned to reduce risk before one defect is reproduced across thousands of interactions. Without liability, speed is rewarded while precautions become optional.
[P1.6] The standard also promotes better innovation rather than suppressing it. Predictable responsibility encourages safety engineering, documentation, auditing, insurance, and careful deployment. It favors firms that invest in reliability over firms that gain market share by externalizing preventable harms. Truly unforeseeable behavior remains outside the rule; unavoidable residual risk remains outside it; reasonable safeguards provide a clear defense.
[P1.7] The decisive principle is simple: power over risk should carry responsibility for preventable consequences. When providers could reasonably foresee harm, could reasonably reduce it, and nevertheless deploy without those protections, leaving the victim alone with the loss is neither efficient nor just.

## Turn 2: CON Opening

- model: gpt-6-astra-high
- raw_words: 323
- clipped_words: 323
- claim_ids: [C1.1], [C1.2], [C1.3], [C1.4], [C1.5], [C1.6], [C1.7], [C1.8]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[C1.1] Responsibility should follow meaningful control over a harmful use, not merely the ability to alter a model. PRO’s proposal sounds narrow because it says “foreseeable” and “reasonable.” But those words conceal the central problem: a safeguard that is reasonable in one deployment can be obstructive or dangerous in another.
[C1.2] Consider a general-purpose model used by a hospital to summarize records. The hospital chooses which records enter, whether clinicians verify summaries, and whether outputs influence treatment automatically. The provider can anticipate medical mistakes, but it cannot determine the appropriate clinical workflow across every customer. Dividing damages afterward does not establish which upstream precaution was actually appropriate.
[C1.3] Foreseeability of an application is not control over its consequences.
[C1.4] That distinction matters because model safeguards involve competing risks, not simply installing a missing brake. Stronger refusals can block legitimate medical information. More monitoring can expose sensitive conversations. Tighter access restrictions can exclude researchers and small developers.
[C1.5] A product-liability-style duty invites courts to judge these general design choices through the lens of a particular injury, after the outcome is known. PRO calls reasonable safeguards a “clear defense”; their adequacy is precisely what expensive litigation would contest.
[C1.6] Providers would therefore have incentives to minimize legally exposed uses, not necessarily total harm. Blanket refusals, intrusive monitoring, and closed distribution are easier to document than nuanced assistance. Large firms can absorb litigation and compliance costs more readily than smaller competitors. These are foreseeable costs of the proposed incentive structure, not arguments that safety should be optional.
[C1.7] The alternative is enforceable, deployment-specific obligations: clinical validation for medical systems, fraud controls for impersonation services, and accountability for deceptive safety claims or breached commitments. Providers operating those services should meet those duties themselves. That is not immunity; it identifies who must do what before harm occurs.
[C1.8] PRO must justify an additional, general provider duty over downstream model behavior. Its qualifiers do not supply that justification. Accountability works best when obligations track actual operational control.

## Turn 3: PRO Rebuttal 1

- model: gpt-5.6-high
- raw_words: 337
- clipped_words: 337
- claim_ids: [P2.1], [P2.2], [P2.3], [P2.4], [P2.5], [P2.6], [P2.7], [P2.8]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[P2.1] CON treats “operational control” as though only the last actor in a chain can meaningfully prevent harm. That is false. A hospital controls clinician review; the provider controls model design, evaluations, access architecture, known failure warnings, and updates. If negligent integration alone causes injury, the proposition does not reach the provider.
[P2.2] If a provider concealed a known medical failure mode or skipped basic testing while promoting that use, downstream responsibility does not erase upstream responsibility. Comparative liability handles precisely this shared-control problem.
[P2.3] Competing safeguards do not defeat a reasonableness standard; they are what the standard evaluates. Privacy-invasive monitoring may be unreasonable where local testing, rate limits, warnings, or restricted capabilities would work better. A safeguard need not eliminate every risk, and courts need not dictate one universal design. They ask the narrower question: given what the provider knew before deployment, was there a proportionate precaution that would likely have prevented this harm?
[P2.4] The possibility of contested cases is no argument for categorical immunity.
[P2.5] CON’s “deployment-specific obligations” are compatible with our rule but incomplete. Some hazards arise from provider-controlled features that customers cannot inspect or repair. Suppose a provider knows its hosted model can be induced through a trivial prompt to reveal another user’s private information, yet deploys without isolation or testing. Telling every customer to develop its own sectoral regulation misses both the source of the defect and the cheapest prevention point.
[P2.6] Provider responsibility is “general” only in legal principle; its application remains specific to the risk, deployment, and omitted safeguard.
[P2.7] The chilling-effect claim also runs backward. Blanket refusals and intrusive surveillance are not automatically reasonable, so they do not guarantee protection from liability. Proportionate documentation, testing, warnings, and access controls do. That rewards nuanced safety rather than maximal restriction.
[P2.8] CON ultimately offers obligations without a remedy when provider negligence contributes to harm. Our rule tracks actual control more accurately: each actor answers for the risks it could foresee and reasonably reduce. Victims should not bear preventable losses simply because responsibility was distributed across a supply chain.

## Turn 4: CON Rebuttal 1

- model: gpt-6-astra-high
- raw_words: 321
- clipped_words: 321
- claim_ids: [C2.1], [C2.2], [C2.3], [C2.4], [C2.5], [C2.6], [C2.7], [C2.8]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[C2.1] PRO’s strongest examples do not establish the disputed rule. A hosted service leaking another customer’s records breaches a concrete confidentiality duty. Promoting medical use while concealing known failures implicates honest-marketing duties. Enforceable obligations and remedies are appropriate in both cases.
[C2.2] But those examples support responsibility for specific activities, not an additional product-style duty extending across foreseeable uses of a general-purpose model.
[C2.3] Comparative liability does not bridge that gap. It allocates responsibility after identifying a breached duty; it does not tell us which actor should have implemented which safeguard. Knowing more about model failure modes does not mean knowing more about a hospital’s records, verification procedures, or clinical consequences. A provider’s ability to change outputs is relevant, but not sufficient to establish that upstream restriction was the appropriate precaution.
[C2.4] PRO asks whether a precaution would “likely have prevented this harm.” That focuses attention on the injured claimant, while the costs of restricting useful behavior fall on other users. Reasonableness can theoretically weigh both. The incentive problem remains: a provider faces a concrete damages claim for harmful assistance, but generally no comparable claim for assistance never offered. The law need not endorse overrestriction for liability to encourage it.
[C2.5] Withdrawing a capability reduces future exposure even when it is worse for users overall.
[C2.6] That directly answers PRO’s claim that blanket refusals offer no guaranteed defense. Providers do not need a judicial declaration that refusal was reasonable; they can avoid generating the contested output altogether. Testing and documentation, by contrast, remain disputable after an injury. The issue is therefore not merely litigation expense.
[C2.7] It is whether the proposed rule rewards socially valuable precautions or legally defensive withdrawal.
[C2.8] My alternative is not “obligations without a remedy.” Deployment-specific duties should be enforceable against whoever performs the relevant activity, including providers. PRO must show what this broader rule adds beyond those duties—and why that addition outweighs its distorted incentives. Two clear misconduct examples do not answer that question.

## Turn 5: PRO Pressure Questions

- model: gpt-5.6-high
- raw_words: 64
- clipped_words: 64
- claim_ids: [P3.1], [P3.2]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[P3.1] Q1: If deployment-specific rules have not anticipated a provider-controlled failure, does your alternative deny compensation even when the provider knew the risk and omitted a cheap safeguard—and if not, what legal principle supplies the remedy?
[P3.2] Q2: Why would bounded liability for foreseeable, preventable harm cause more overrestriction than your own enforceable safety duties, especially when proportionate testing, warnings, and access controls satisfy our standard?

## Turn 6: CON Pressure Questions

- model: gpt-6-astra-high
- raw_words: 63
- clipped_words: 63
- claim_ids: [C3.1], [C3.2]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[C3.1] Q1: What concrete harm would your rule remedy that enforceable confidentiality, honest-marketing, and deployment-specific safety duties would not, and what makes the missing precaution the provider’s responsibility rather than the deployer’s?
[C3.2] Q2: If withdrawing a useful capability avoids output-related claims, while retaining it leaves safeguards open to challenge, what counteracts the incentive to withdraw when harms from denied assistance carry no comparable liability?

## Turn 7: PRO Rebuttal 2

- model: gpt-5.6-high
- raw_words: 314
- clipped_words: 314
- claim_ids: [P4.1], [P4.2], [P4.3], [P4.4], [P4.5], [P4.6]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[P4.1] A1: A concrete gap is a provider knowingly releasing realistic voice cloning with no consent check, access control, or abuse throttling, followed by a foreseeable impersonation scam. Confidentiality and honest-marketing duties do not remedy the victim’s financial loss, and a tailored voice-cloning rule may not yet exist. The omitted provider-side access design is the provider’s responsibility because only it controls that gateway and can protect every deployment at once. The scammer remains liable for fraud, and a deployer answers for its own negligence; shared fault does not erase the upstream breach.
[P4.2] A2: Three things counteract withdrawal: providers earn revenue from useful capabilities; competitors can offer them with defensible safeguards; and our rule does not impose liability merely because a harmful output occurred. It applies only when a claimant proves causation and a reasonable omitted precaution. Reasonableness weighs the capability’s social value and effects on other users, so withdrawal is commercially costly but not legally necessary. CON’s enforceable duties create the same alleged asymmetry: one can avoid a clinical-validation claim by leaving medicine.
[P4.3] If that incentive defeats our rule, it defeats theirs too.
[P4.4] CON’s alternative therefore faces a dilemma. If duties exist only where lawmakers or contracts have already named a sector and precaution, preventable harms in new uses fall through the cracks. If courts may instead enforce a flexible duty whenever a provider could reasonably prevent foreseeable harm, CON has recreated our principle while denying it a coherent label.
[P4.5] The key comparison is not liability versus frictionless innovation; both sides impose duties. It is whether accountability follows every actor’s actual control or stops at category boundaries. Our test requires harm, foreseeability, causation, and an omitted proportionate safeguard, while permitting fault to be divided. That burden filters weak claims while preserving a remedy when the informed risk-controller ignored an avoidable danger.
[P4.6] CON’s chilling-effect concern applies equally to its own regime; its accountability gap does not.

## Turn 8: CON Rebuttal 2

- model: gpt-6-astra-high
- raw_words: 313
- clipped_words: 313
- claim_ids: [C4.1], [C4.2], [C4.3], [C4.4], [C4.5], [C4.6]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[C4.1] A1: Ordinary negligence can enforce duties arising from a concrete service undertaking; lawmakers need not name every technical failure. But if no applicable duty exists, yes, compensation from that provider is not guaranteed. Knowledge and a cheap intervention do not alone establish responsibility: “cheap” says nothing about lost utility or risks shifted onto others. Responsibility should attach to an activity undertaken, not merely the ability to alter downstream risks.
[C4.2] A2: Both regimes can discourage deployment; I claim a difference in degree, not immunity from tradeoffs. A deployment-specific standard can specify validation requirements before launch. PRO’s rule leaves providers contesting which additional safeguards were reasonable across foreseeable uses after injuries occur. Testing and warnings may ultimately prevail, but they are evidence in litigation, not the assured protection PRO promises.
[C4.3] That uncertainty increases the relative attraction of withdrawal.
[C4.4] PRO’s voice-cloning example identifies a specific service whose operator controls access to an impersonation-enabling capability. Consent and access duties for that service fit my alternative, including when its operator is the model provider. If such a duty is missing, that supports establishing it. It does not establish that providers of general-purpose models should bear an additional duty for behavior across downstream applications.
[C4.5] Revenue and competition do not answer the withdrawal incentive. Revenue captures what users pay, not all the social value of assistance, while competitors face the same liability exposure. Judicial consideration of social value helps only if a provider first accepts the risk and expense of defending continued access. Defined duties narrow that gamble; PRO’s open-ended standard expands it.
[C4.6] The decisive comparison is marginal benefit, not accountability versus immunity. PRO’s clearest benefits are available through narrower, enforceable duties. Its broader rule adds uncertain exposure across general-purpose uses, encouraging withdrawal precisely where no one compensates users for lost assistance. That is not a demonstrated improvement in safety; it is a reason to reject the additional liability framework.

## Turn 9: PRO Closing

- model: gpt-5.6-high
- raw_words: 217
- clipped_words: 217
- claim_ids: [P5.1], [P5.2], [P5.3], [P5.4]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[P5.1] The decisive concession is CON’s: where no applicable duty already exists, compensation from the provider is not guaranteed—even when it knew the risk and omitted a reasonable precaution. That is the accountability gap the proposition closes. Emerging harms will not always arrive inside a prewritten sectoral box. A legal framework that protects victims only after lawmakers have named each capability and precaution systematically lags the technology.
[P5.2] CON cannot escape by invoking ordinary negligence for a “concrete service undertaking.” Deploying and managing a model is itself an undertaking. If that negligence principle flexibly asks whether the provider foreseeably caused harm by omitting a reasonable provider-side safeguard, CON has recreated our rule. If it does not, the victim bears the loss merely because the danger crossed a category boundary.
[P5.3] Calling a model “general-purpose” does not erase the provider’s specific control over testing, warnings, access, and updates. Nor does our rule make providers insurers: harm, causation, foreseeability, and an omitted proportionate safeguard must all be proved. CON offers only the possibility of somewhat greater caution, a concern shared by every enforceable safety duty. Against that speculation stands its admitted certainty: preventable victims can receive no remedy from a culpable risk-controller.
[P5.4] When a provider could reasonably prevent a foreseeable harm and chose not to, legal silence should not subsidize that omission.

## Turn 10: CON Closing

- model: gpt-6-astra-high
- raw_words: 196
- clipped_words: 196
- claim_ids: [C5.1], [C5.2], [C5.3], [C5.4], [C5.5], [C5.6]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[C5.1] The decisive issue is not whether victims deserve remedies. It is whether this additional provider duty improves prevention rather than rewarding withdrawal.
[C5.2] PRO calls providers “culpable” before resolving what obligation they breached. Calling model deployment an “undertaking” does not establish responsibility for precautions throughout downstream workflows. Our alternative permits enforceable negligence duties grounded in a concrete service; it does not require lawmakers to anticipate every technical failure. An uncompensated injury is not, by itself, proof that an additional upstream duty is justified.
[C5.3] That matters because the broader duty changes incentives asymmetrically. Retain useful assistance, and safeguards remain contestable after an injury. Withdraw it, and output-related exposure disappears; users losing beneficial assistance generally have no comparable claim. Revenue offsets some pressure, but does not capture all that lost social value.
[C5.4] Saying courts can weigh utility does not remove this incentive before launch.
[C5.5] Both approaches impose safety costs. Defined, activity-specific duties narrow the gamble; PRO expands it without demonstrating an additional benefit that narrower accountability cannot supply. The motion is not necessary to remedy a breached confidentiality or access-control duty. Its contested addition is open-ended upstream exposure.
[C5.6] Reward precautions tied to actual responsibility, not retreat from useful capabilities.
